Robak, T.; Janus, A.; Jamroziak, K.; Tiacci, E.; Kreitman, R.J.
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. J. Clin. Med. 2021, 10, 2800.
https://doi.org/10.3390/jcm10132800
AMA Style
Robak T, Janus A, Jamroziak K, Tiacci E, Kreitman RJ.
Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine. 2021; 10(13):2800.
https://doi.org/10.3390/jcm10132800
Chicago/Turabian Style
Robak, Tadeusz, Agnieszka Janus, Krzysztof Jamroziak, Enrico Tiacci, and Robert J. Kreitman.
2021. "Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox" Journal of Clinical Medicine 10, no. 13: 2800.
https://doi.org/10.3390/jcm10132800
APA Style
Robak, T., Janus, A., Jamroziak, K., Tiacci, E., & Kreitman, R. J.
(2021). Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. Journal of Clinical Medicine, 10(13), 2800.
https://doi.org/10.3390/jcm10132800